Revenue: |
License revenue |
0 |
Expenses: |
Research and development |
8.93M |
General and administrative |
2.77M |
Total expenses |
Loss before other income |
-11.7M |
Other income: |
Interest income |
Other income, net |
Gain on warrant derivative liability |
246.21K |
Gain on sale of affiliate's shares - RXi Pharmaceutical |
Loss before provision for income taxes |
Provision for income taxes |
Net income (loss) |
-12.18M |
Other comprehensive income (net of tax) |
Unrealized gain on available-for-sale securities |
Comprehensive income (loss) |
Basic net income (loss) per share (in dollars per share) |
Basic weighted average shares outstanding (in shares) |
Diluted net income (loss) per share (in dollars per share) |
Diluted weighted average shares outstanding (in shares) |